Upgrade to SI Premium - Free Trial

Morgan Stanley Resumes Pfizer (PFE) at Overweight, Sees Growth Acceleration on Horizon

June 4, 2019 7:40 AM
Morgan Stanley analyst David Risinger resumes coverage on Pfizer (NYSE: PFE) with a Overweight rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments New Coverage